首页 > 市场调查报告书 > 製药

骨疾病

骨质疏鬆症药物市场规模、份额和成长分析（按药物类别、给药途径、适应症和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1900301

骨质疏鬆症药物市场规模、份额和成长分析（按药物类别、给药途径、适应症和地区划分）－2026-2033年产业预测

Osteoporosis Drugs Market Size, Share, and Growth Analysis, By Drug Class (Rank Ligand Inhibitors, Bisphosphonates), By Route of Administration (Oral, Injectable), By Application, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，骨质疏鬆症药物市场规模将达到 75.9 亿美元，到 2025 年将达到 78.5 亿美元，到 2033 年将达到 102.5 亿美元，在预测期（2026-2033 年）内，复合年增长率为 3.4%。

骨质疏鬆症治疗市场正经历显着的进步，这主要得益于创新医疗技术的推动，特别是新型药物输送系统和先进的骨质密度检测设备。这些发展拓宽了治疗选择，改善了患者的治疗效果，并提振了骨质疏鬆症治疗市场的未来前景。这些药物旨在预防、治疗和控制骨质疏鬆症——一种以骨量减少和骨骼脆弱性增加为特征的疾病——它们能够增强骨骼强度，减缓骨质流失，并降低骨折风险。市场成长的驱动力来自持续的药物研发活动、对综合健康解决方案日益增长的需求以及对骨折预防的日益重视。此外，新兴的生物疗法，例如靶向单株抗体，有望为对传统疗法无效的患者提供有效的替代方案，而机器学习和人工智慧等创新技术正在简化研发流程。

骨质疏鬆症药物市场驱动因素

全球骨质疏鬆症治疗市场的主要驱动因素之一是人口老化和预期寿命延长导致骨质疏鬆症及骨骼相关疾病的盛行率不断上升。人口结构变化使更多人面临骨骼密度降低等疾病的风险，进而导致骨折及相关併发症的发生率增加。这一日益严重的健康问题推动了对有效骨质疏鬆症治疗药物的需求成长，并促进了药物研发。此外，医护人员和患者对骨质疏鬆症管理和预防措施的认识不断提高，也进一步推动了市场发展，为创新治疗方案和策略性市场成长创造了机会。

骨质疏鬆症药物市场的限制

全球骨质疏鬆症治疗市场的主要限制因素之一是创新治疗方法的高成本，这可能会限制患者的用药途径。随着人口老化和骨质疏鬆症盛行率的上升，对有效治疗方法的需求日益增长，但许多患者可能无法负担这些先进药物的费用，或没有医疗保险。此外，治疗方案的复杂性和潜在的副作用可能会降低患者的依从性，从而阻碍市场成长。另外，人们越来越重视成本效益高的医疗保健解决方案，这可能会导致人们更倾向于选择学名药，这可能会影响市场动态。

骨质疏鬆症药物市场趋势

骨质疏鬆症治疗市场正呈现出显着且不断增长的趋势，即采用注射疗法，特别是成骨剂和成骨抑制剂，这些疗法以其高效性和持久作用而着称。这些注射疗法特别适用于重度骨质疏鬆症患者，有效满足了重要的医疗需求，并推动了市场需求。随着医疗服务提供者越来越重视个人化治疗方案和改善患者预后，向这些先进治疗方法的转变凸显了骨质疏鬆症治疗领域向创新和永续解决方案发展的更广泛趋势。这一趋势体现了改善骨质疏鬆症患者生活品质的整体性方法。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Amgen Inc.（US）
Eli Lilly and Company（US）
Merck & Co., Inc.（US）
Novartis International AG（Switzerland）
Pfizer Inc.（US）
GlaxoSmithKline plc（UK）
Radius Health, Inc.（US）
UCB SA（Belgium）
Teva Pharmaceutical Industries Ltd.（Israel）
Roche Holding AG（Switzerland）
Bristol-Myers Squibb Company（US）
Sanofi SA（France）
AbbVie Inc.（US）
AstraZeneca PLC（UK）
Hologic, Inc.（US）
Lundbeck A/S（Denmark）
Eisai Co., Ltd.（Japan）
Ferring Pharmaceuticals（Switzerland）
Sandoz International GmbH（Switzerland）
Servier Laboratories（France）
Bayer AG（Germany）
Grunenthal GmbH（Germany）

简介目录

Product Code: SQMIG35I2282

Osteoporosis Drugs Market size was valued at USD 7.59 Billion in 2024 and is poised to grow from USD 7.85 Billion in 2025 to USD 10.25 Billion by 2033, growing at a CAGR of 3.4% during the forecast period (2026-2033).

The osteoporosis drug market is witnessing significant advancements fueled by innovative medical technologies, including novel medication delivery systems and enhanced bone density measurement devices. These developments yield a broader array of treatment options, yielding improved patient outcomes and enhancing the future market prospects for osteoporosis therapies. Designed to prevent, treat, and manage osteoporosis-which involves decreased bone mass and increased fragility-these medications bolster bone strength, slow down loss, and diminish fracture risk. The market growth is driven by ongoing drug discovery, heightened demand for integrated health solutions, and a focus on fracture prevention. Additionally, emergent biologic therapies, such as targeted monoclonal antibodies, promise effective alternatives for patients with non-responsiveness to traditional treatments, while innovations like machine learning and artificial intelligence are streamlining research and development efforts.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoporosis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoporosis Drugs Market Segments Analysis

Global Osteoporosis Drugs Market is segmented by Drug Class, Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Branded, and Generic. Based on Type, the market is segmented into Bisphosphonates, Parathyroid Hormone, Calcitonin, Selective Estrogen Inhibitor Modulator, Rank Ligand Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Osteoporosis Drugs Market

One key market driver for the Global Osteoporosis Drugs Market is the increasing prevalence of osteoporosis and bone-related disorders, largely attributed to an aging population and rising life expectancy. As the demographic landscape shifts, more individuals are at risk for conditions characterized by decreased bone density, leading to a higher incidence of fractures and related complications. This growing health concern prompts greater demand for effective osteoporosis treatments, driving pharmaceutical research and development. Additionally, heightened awareness about osteoporosis management and preventive measures among healthcare professionals and patients further fuels the market, creating opportunities for innovative therapeutic solutions and strategic market growth.

Restraints in the Osteoporosis Drugs Market

One key market restraint for the global osteoporosis drugs market is the high cost of innovative therapies, which can limit accessibility for patients. As the population ages and the prevalence of osteoporosis increases, the demand for effective treatments rises; however, many patients may be unable to afford these advanced medications or lack insurance coverage. Additionally, the complexity of treatment regimens and potential side effects can discourage adherence, further hindering market growth. Furthermore, the increasing emphasis on cost-effective healthcare solutions may lead to a preference for generic medications over pricier branded options, impacting the overall market dynamics.

Market Trends of the Osteoporosis Drugs Market

The osteoporosis drugs market is witnessing a notable trend towards the increasing adoption of injectable therapies, particularly Rank Ligand Inhibitors and anabolic agents, which are recognized for their significant efficacy and extended duration of action. These injectable treatments are particularly well-suited for patients with severe osteoporosis, effectively addressing critical health needs and driving demand within the market. As healthcare providers emphasize tailored treatment options and improved patient outcomes, the shift towards these advanced therapeutic modalities underscores a broader movement towards innovative, long-lasting solutions in osteoporosis care. This trend reflects an overall commitment to enhancing quality of life for individuals affected by this chronic condition.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
PESTEL Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Osteoporosis Drugs Market by Drug Class

Market Overview
Branded
Generic

Osteoporosis Drugs Market by Type

Market Overview
Bisphosphonates
Parathyroid Hormone
Calcitonin
Selective Estrogen Inhibitor Modulator
Rank Ligand Inhibitor
Others

Osteoporosis Drugs Market by Distribution Channel

Market Overview
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy

Osteoporosis Drugs Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radius Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Servier Laboratories (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grunenthal GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments